Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients - Gaudin, Olivier; Seta, Vannina; Alexandre, Marina; Bohelay, Gérôme; Aucouturier, Françoise; Mignot-Grootenboer, Sabine; Ingen-Housz-Oro, Saskia; Bernardeschi, Céline; Schneider, Pierre; Mellottee, Benoît; Caux, Frédéric; Prost-Squarcioni, Catherine (Frontiers in immunology, 2018)
Keywords: Aged; Aged, 80 and over; Autoantibodies - immunology; Autoantigens - immunology; autoimmune bullous diseases; diabetes mellitus; Diabetes Mellitus, Type 2 - drug therapy; dipeptidyl peptidase IV inhibitor; Dipeptidyl-Peptidase IV Inhibitors - adverse effects; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; Female; fibrosis; gliptin; Humans; Immunology; Male; Middle Aged; Mucous Membrane - drug effects; Mucous Membrane - pathology; mucous membrane pemphigoid; Pemphigoid, Benign Mucous Membrane - chemically induced; Pemphigoid, Benign Mucous Membrane - pathology; Pemphigoid, Bullous - chemically induced; Pemphigoid, Bullous - pathology; Retrospective Studies; Skin - immunology; gliptin; adverse drug reaction; drug-accountability study; mucous membrane pemphigoid; diabetes mellitus; fibrosis; autoimmune bullous diseases; dipeptidyl peptidase IV inhibitor